Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream

J Clin Oncol. 2008 Nov 1;26(31):5011-3. doi: 10.1200/JCO.2008.18.3137. Epub 2008 Sep 2.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / mortality
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Epirubicin / administration & dosage
  • ErbB Receptors / analysis
  • Female
  • Fluorouracil / administration & dosage
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Methotrexate / administration & dosage
  • Patient Selection*
  • Receptor Protein-Tyrosine Kinases / analysis*
  • Receptor, ErbB-2 / analysis
  • Receptor, ErbB-3 / analysis
  • Receptor, ErbB-4
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Biomarkers, Tumor
  • Epirubicin
  • Cyclophosphamide
  • EGFR protein, human
  • ERBB2 protein, human
  • ERBB4 protein, human
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases
  • Receptor, ErbB-2
  • Receptor, ErbB-3
  • Receptor, ErbB-4
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen